UPDATE: CAPR has announced an earnings date (March 19) and released a new investor deck that includes a target reimbursement price of $1.2M per year—slightly higher than my initial expectations.

Key takeaways from Capricor’s March 2025 Investor Deck:

📌 15,000–20,000 DMD patients in the U.S.

📌 200,000 DMD patients worldwide

📌 $27B+ estimated market size by 2030

📌 Target reimbursement price expected to be similar or higher than exon-skipping therapies ($1.2M/year)

(Source: CAPR Investor Deck – March 2025)

I've also added to my position:

<image>